Osteitis secondary to BCG vaccine in immunocompetent patients
| Autor: | Rodolfo Rodríguez Jurado, Ana Isabel Quesada Tortoriello, Diego Mauricio Galvis Trujillo, Bárbara Varela Ruiz, Miroslava Lindoro Silva, Hugo Juárez Olguín, Eduardo Arias de la Garza, Napoleón González Saldaña, Agustín De Colsa Ranero |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Male
osteitis medicine.medical_specialty Antitubercular Agents MEDLINE 03 medical and health sciences 0302 clinical medicine children Clarithromycin medicine Humans Clinical Case Report 030212 general & internal medicine Bacillus (shape) biology business.industry Infant General Medicine Bone Diseases Infectious medicine.disease biology.organism_classification Mycobacterium bovis Dermatology tuberculosis Child Preschool 030220 oncology & carcinogenesis BCG Vaccine Infectious etiology Female Osteitis Complication business BCG vaccine Research Article Pediatric population |
| Zdroj: | Medicine |
| ISSN: | 1536-5964 0025-7974 |
| Popis: | Rationale: Osteitis corresponds to a rare but potentially serious complication reported in pediatric population after the application of the Bacillus Calmette-Guerin (BCG) vaccine. In the present study, 3 clinical cases associated with this entity are reported. Patient concerns: The 1st case corresponds to a 1-year-old female patient who presented an increase in the volume of the right pelvic limb after BCG application. The second case is a 2-year-old male who began with an increase in volume, overactive gait and pain at the level of the left knee on walking that began after a trauma in the left low limb. The 3rd case corresponds to a 3-year-old patient who started with intense pain and limitation for ambulation. Diagnosis: Both the radiographical and histological studies presented data suggestive of infection by Mycobacterium tuberculosis complex, corroborated through biopsy and genotyping analysis with the isolation of Mycobacterium bovis as the causal agent. Interventions: The basic treatment scheme was based on Ethambutol, Rifampicin, Pyrazinamide, and Isoniazid. When M. bovis was typified, clarithromycin was added in the treatment. Outcomes: Osteitis secondary to BCG vaccine usually has a favorable evolution, especially in immunocompetent patients. Lessons: It was possible to confirm the association of BCG vaccine with the clinical picture of the patients who presented improvement after the start of antimicrobial management. Osteitis secondary to BCG vaccine usually presents a favorable evolution, especially in immunocompetent patients; however, the involvement of joint, growth discs and vertebrae increases the risk of presenting long-term sequels. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|